奥妥珠单抗相关不良反应的防治研究  

Prevention and Treatment of Obinutuzumab Related Adverse Drug Reactions

作　　者：李岩 闫雨婷 陈佳[3] 李轶[1] 谢诚[1] 朱建国[1] 夏凡[1] LI Yan;YAN Yuting;CHEN Jia;LI Yi;XIE Cheng;ZHU Jianguo;XIA Fan(Dept.of Pharmacy,the First Affiliated Hospital of Soochow University,Jiangsu Suzhou 215006,China;Dept.of Pharmacy,the First Affiliated Hospital of Nanjing Medical University,Jiangsu Suzhou 210029,China;Dept.of Hematology,the First Affiliated Hospital of Soochow University,Jiangsu Suzhou 215006,China)

机构地区：[1]苏州大学附属第一医院药学部,江苏苏州215006 [2]南京医科大学附属第一医院药学部,南京210029 [3]苏州大学附属第一医院血液科,江苏苏州215006

出　　处：《中国医院用药评价与分析》2024年第7期893-896,共4页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：中国研究型医院学会药物评价专委会临床重点药品的使用监测和评价研究专项课题(No.Y2022FH-YWPJ01-102)。

摘　　要：奥妥珠单抗是全球首个人源化、糖基化修饰的Ⅱ型抗CD20单克隆抗体,与Ⅰ型CD20单克隆抗体利妥昔单抗相比,滤泡性淋巴瘤患者使用奥妥珠单抗获益显著。临床试验数据显示,中国人群使用奥妥珠单抗的输液反应、血小板减少及中性粒细胞减少等相关不良反应发生率更高。本文从奥妥珠单抗常见的相关不良反应类型和机制、防治措施及黑框警告内容进行系统性综述,旨在为真实世界安全用药提供相关参考。Obinutuzumab is the first humanized,glycosylation-modified typeⅡanti-CD20 monoclonal antibody in the world.Compared with rituximab(typeⅠanti-CD20 monoclonal antibody),obinutuzumab is more effective in the treatment of follicular lymphoma.Clinical trial data have shown a higher incidence of adverse drug reactions related to infusion reactions,thrombocytopenia and neutropenia with the use of otuzumab in the Chinese population.This thesis systematically reviews the common types,mechanisms of related adverse drug reactions,preventive measures and black box warnings of obinutuzumab related adverse drug reactions,with the aim of providing relevant references for safe medication in the real world.

关 键 词：奥妥珠单抗 CD20 不良反应 预防 治疗 

分 类 号：R979.1[医药卫生—药品]